These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26265611)

  • 1. CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.
    Liu J; Nie XY; Zhang Y; Lu Y; Shi LW; Wang WM
    Chin Med J (Engl); 2015 Aug; 128(16):2183-8. PubMed ID: 26265611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
    Tang N; Yin S; Sun Z; Xu X; Qin J
    Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
    Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.
    Nagashima Z; Tsukahara K; Morita S; Endo T; Sugano T; Hibi K; Himeno H; Fukui K; Umemura S; Kimura K
    J Cardiol; 2013 Sep; 62(3):158-64. PubMed ID: 23886632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity.
    Nie XY; Li JL; Zhang Y; Xu Y; Yang XL; Fu Y; Liang GK; Lu Y; Liu J; Shi LW
    J Zhejiang Univ Sci B; 2017 Jan.; 18(1):37-47. PubMed ID: 28070995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
    Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
    Jiang M; You JH
    Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
    Peng W; Shi X; Xu X; Lin Y
    Cardiovasc Ther; 2019; 2019():3470145. PubMed ID: 31772608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
    Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
    Wu H; Qian J; Sun A; Wang Q; Ge J
    Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
    Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
    Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.
    Zhu KX; Song PY; He-Li ; Li MP; Du YX; Ma QL; Peng LM; Chen XP
    Eur J Clin Pharmacol; 2021 Mar; 77(3):359-368. PubMed ID: 33089397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.
    Marcucci R; Giusti B; Paniccia R; Gori AM; Saracini C; Valente S; Giglioli C; Parodi G; Antoniucci D; Gensini GF; Abbate R
    Platelets; 2012; 23(8):586-93. PubMed ID: 22390861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
    Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
    J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
    J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of individualized antiplatelet therapy, based on CYP2C19 genotyping, on platelet function in patients underwent percutaneous coronary intervention.
    Zhang M; Wang J; Zhang Y; Zhang P; Chao Y; Gao M; Hou Y
    Perfusion; 2022 Jan; 37(1):78-85. PubMed ID: 33300437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.